Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab in chronic spontaneous urticaria refractory to H1 antihistamines
jRCT2080225105Phase 3Completed
- Sponsor
- Sanofi
- Start
- Mar 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of dupilumab in chronic idiopathic urticaria (CIU) (6 arms), sponsored by Sanofi. Primary endpoint: Clinical efficacy on CSU symptoms. Started Mar 2020; status: completed.
02
Drugs
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on jRCT2080225105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225105.